Zenyth Partners
Zenyth Partners identifies itself as a healthcare investor and business builder focused exclusively on specialized healthcare services businesses. It describes a concentrated, hands-on investor-operator model, with generally majority or control investments and operational support for portfolio companies.
Zenyth Partners publicly targets U.S.-based healthcare services businesses with $0-10mm+ EBITDA at entry.
It states that it invests $40-60mm of equity capital per platform, or more when co-investment is available, and generally makes majority/control investments while promoting significant equity ownership for founders, clinicians, and management teams.[1][2][3][4][9]
What does Zenyth Partners invest in?
Zenyth Partners identifies itself as a healthcare investor and business builder focused on growing specialized healthcare service businesses. Its official About page describes the firm as an investment firm focused exclusively on healthcare services businesses.
Zenyth also describes a hands-on investor-operator model in which it acts as an operational and strategic partner to portfolio companies.[1][2][3]
Zenyth states that each fund invests in a limited number of high-conviction platforms, deploys capital patiently over time, uses financial leverage conservatively, and does not rely on financial engineering to drive returns.
Its stated portfolio-acceleration services include add-on M&A execution, capital raising, executive recruiting and support, growth optimization, technology strategy and integration, and vendor management and procurement.[3]
Owners evaluating a financial buyer can compare the offer with independent valuation analysis, understand how acquirers approach transactions through Auxo’s buy-side M&A process guide, and consider whether a full or partial sale best fits their objectives.
Published criteria: Zenyth states that it targets businesses with $0-10mm+ EBITDA at entry and invests $40-60mm of equity capital per platform, or more if available co-investment is pursued. It generally makes majority/control investments and uses financial leverage conservatively.[3]
What should a business owner evaluate before considering a transaction with Zenyth Partners?
An owner evaluating Zenyth should clarify the proposed platform thesis, the application of the $0-10mm+ EBITDA entry range to the relevant healthcare subsector, and whether the proposed transaction would be structured as a majority/control investment.
Because Zenyth promotes significant equity ownership for founders, clinicians, and management teams, an owner should also ask about rollover expectations, governance rights, clinical-autonomy provisions, management incentive terms, and reserved matters. The proposed debt levels, add-on funding and integration approach, transaction fees, exclusivity obligations, and any earnout provisions should be confirmed directly.
The cited official Approach page does not state an expected investment holding period, ownership-duration range, or standard exit timetable, so the owner should request the expected ownership horizon for the proposed platform.[3]
What current investment thesis and platform gaps are priorities for the proposed transaction
How does Zenyth apply the $0-10mm+ EBITDA entry range to this healthcare subsector and company
What percentage of equity is typically rolled by founders and management in a majority investment
What companies does Zenyth Partners target?
Zenyth states that its investment-stage criterion is $0-10mm+ EBITDA at entry. It also states that it invests $40-60mm of invested equity capital per platform, or more if it seeks available co-investment opportunities.
The firm generally makes majority/control investments and promotes significant equity ownership for partner founders, clinicians, and management teams.[3]
Zenyth states that its focus is high-quality healthcare services businesses aligned with its investment theses. Publicly identified areas include renal and chronic-care management, applied behavior analysis, ophthalmology, dermatology, and dental support organizations.[3][4][5][6][7][8]
Zenyth states that its investment geography is businesses based in the United States.[3]
Zenyth describes a platform-oriented model centered on a limited number of high-conviction platforms. It identifies add-on M&A execution as one of its portfolio-acceleration services.
Its public portfolio includes platforms founded by Zenyth, including ReFocus Eye Health, Helping Hands Family, and Renal Care 360.[3][4][5][6]
Zenyth’s official portfolio pages identify ReFocus Eye Health, Helping Hands Family, Renal Care 360, Schweiger Dermatology Group, and The Smilist as portfolio companies.
Zenyth’s portfolio pages state that ReFocus Eye Health was founded by Zenyth in 2018, Helping Hands Family was founded by Zenyth in 2019, and Renal Care 360 was founded in 2018. The pages also describe operating footprints and services for these businesses, including ophthalmology, applied behavior analysis, renal and chronic-care management, dermatology, and dental services.[4][5][6][7][8]
Evolve Orthopedic Partners announced its formation on August 12, 2025, with a foundational partnership with OrthoNY, and identified Zenyth Partners as its healthcare investment-firm backer.
Zenyth Partners announced on July 7, 2025, that Zenyth Partners II closed with $375 million of aggregate capital commitments. Separately, Citizens M&A Advisory announced on March 8, 2024, that Ellipse Eye Group was sold to ReFocus Eye Health, a Zenyth portfolio company.[9][10][11]
What is not clear from Zenyth Partners's public investment criteria?
The cited official Approach page does not publish a universal transaction-fee percentage, minimum fee, valuation-multiple range, or standardized seller-consideration schedule.
The cited official ReFocus portfolio page identifies the platform and operating footprint but does not disclose purchase price, enterprise value, financing terms, seller proceeds, or rollover-equity terms for Zenyth’s 2018 formation of ReFocus.
The cited Evolve Orthopedic Partners announcement describes the OrthoNY partnership and Zenyth’s backing but does not disclose transaction consideration, valuation, leverage, seller rollover percentage, or governance economics. The cited official Approach page does not state an expected investment holding period, ownership-duration range, or standard exit timetable.[3][4][9]
Questions to ask when evaluating Zenyth Partners as a buyer or investment partner
What current investment thesis and platform gaps are priorities for the proposed transaction?
How does Zenyth apply the $0-10mm+ EBITDA entry range to this healthcare subsector and company?
What percentage of equity is typically rolled by founders and management in a majority investment?
What governance, clinical-autonomy, and reserved-matter rights would be available to physician owners?
How would add-on acquisitions be funded and integrated?
What debt levels, management incentive terms, transaction fees, exclusivity obligations, and earnout provisions would apply?
What is the expected investment or ownership horizon for the proposed platform?
Sources & research notes
- Official website / firm overview
- Official website / firm overview
- Investment approach
- Transaction / portfolio evidence
- Transaction / portfolio evidence
- Transaction / portfolio evidence
- Transaction / portfolio evidence
- Transaction / portfolio evidence
- Transaction / portfolio evidence
- Transaction / portfolio evidence
- Transaction / portfolio evidence
- SEC filing / regulatory record
How this profile was researched
Auxo profiles are prepared from publicly available primary and authoritative sources and reviewed for entity identity, factual support and disclosure consistency. When a fact cannot be supported by the reviewed public record, the profile identifies it as something to confirm directly rather than inferring it.
Independent research profile
This profile was prepared by Auxo Capital Advisors from publicly available information believed to be reliable and is provided solely for informational and educational purposes. It is not an endorsement, recommendation, ranking, solicitation, or representation regarding the profiled firm, its services, qualifications, transaction experience, regulatory status, financial condition, or suitability for any particular person, company, transaction, or investment.
Information obtained from third-party and public sources may be incomplete, inaccurate, outdated, or subject to change, and Auxo Capital Advisors makes no representation or warranty, express or implied, as to its accuracy, completeness, or timeliness. Readers should conduct their own independent diligence and consult appropriate professional advisers before engaging any advisor, intermediary, investor, lender, acquirer, or other transaction counterparty.
Broker-dealer and securities disclosure
Auxo Capital Advisors is an affiliate of Weild & Co., Member FINRA | SIPC. Securities-related activities and securities transactions are conducted through Weild & Co.
Nothing contained on this page constitutes an offer to sell, an offer to purchase, or a solicitation of an offer to buy or sell any security, investment product, or financial instrument. Nothing on this page constitutes investment advice, a recommendation regarding any security, or a recommendation to enter into any transaction with the profiled firm or any other party.
Any securities transaction, capital-raising engagement, investment-banking engagement, or other securities-related activity involving Auxo Capital Advisors or Weild & Co. is subject to applicable regulatory requirements, internal review and approval, suitability and other applicable diligence requirements, and the terms of a separate written engagement or transaction agreement, as applicable.
Inclusion of a third-party firm in this directory does not imply affiliation with, sponsorship by, endorsement by, or any other relationship with Auxo Capital Advisors or Weild & Co. unless expressly stated otherwise.